Noctrix Health develops a clinically validated wearable therapy utilizing Tonic Motor Activation (TOMAC) technology to manage symptoms of Restless Legs Syndrome (RLS). This drug-free solution addresses the significant discomfort and sleep disturbances experienced by millions of Americans affected by RLS, offering a viable alternative to traditional pharmaceutical treatments.
Funding
$60.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
SAFounders
Product
Problem
Restless Legs Syndrome (RLS) affects a significant portion of the adult population, causing intense discomfort, an uncontrollable urge to move the legs, and sleep disturbances. Current treatment options are limited, and many patients on prescription drug therapy still experience worsening symptoms.
Solution
Noctrix Health offers a clinically validated, drug-free wearable therapy utilizing Tonic Motor Activation (TOMAC) technology to manage RLS symptoms. The wearable device, Nidra, is designed to reduce discomfort and sleep disturbances associated with RLS. This therapeutic approach provides a viable alternative for individuals seeking relief from RLS without pharmaceutical intervention.
Target Audience
The primary target audience includes adults experiencing Restless Legs Syndrome (RLS) and seeking a non-pharmaceutical treatment option, as well as healthcare professionals treating patients with RLS.
Features
- Wearable device delivering Tonic Motor Activation (TOMAC) therapy
- Clinically proven to reduce RLS symptoms
- Drug-free alternative to traditional pharmaceutical treatments
- FDA authorized
- New CMS reimbursement codes and payment
- Included in American Academy of Sleep Medicine (AASM) Clinical Practice Guidelines for RLS